| scholarly article | Q13442814 |
| P50 | author | Gerhardt Attard | Q37834810 |
| Shahneen K Sandhu | Q60042780 | ||
| P2093 | author name string | J Hunt | |
| G Maier | |||
| A H M Reid | |||
| D Olmos | |||
| E Thompson | |||
| E Sheridan | |||
| J de Bono | |||
| C Pezaro | |||
| A Zivi | |||
| D Bianchini | |||
| A Mulick Cassidy | |||
| A Sarvadikar | |||
| B Baikady | |||
| J Mezynski | |||
| P433 | issue | 11 | |
| P921 | main subject | docetaxel | Q420436 |
| P304 | page(s) | 2943-2947 | |
| P577 | publication date | 2012-07-05 | |
| P1433 | published in | Annals of Oncology | Q326122 |
| P1476 | title | Antitumour activity of docetaxel following treatment with the CYP17A1 inhibitor abiraterone: clinical evidence for cross-resistance? | |
| P478 | volume | 23 |
| Q33439003 | A multicenter phase I study of cabazitaxel, mitoxantrone, and prednisone for chemotherapy-naïve patients with metastatic castration-resistant prostate cancer: A department of defense prostate cancer clinical trials consortium study |
| Q30248275 | Abiraterone Acetate for the Treatment of Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer: An Evidence Review Group Perspective of an NICE Single Technology Appraisal |
| Q33656820 | Abiraterone acetate and prednisone in chemotherapy-naïve prostate cancer patients: rationale, evidence and clinical utility |
| Q85005790 | Abiraterone acetate for metastatic prostate cancer |
| Q35358010 | Abiraterone acetate in patients with metastatic castration-resistant prostate cancer: long term outcome of the Temporary Authorization for Use programme in France |
| Q39520491 | Abiraterone and its place in the treatment of metastatic CRPC. |
| Q26853635 | Abiraterone in the treatment of metastatic castration-resistant prostate cancer |
| Q90729992 | Abiraterone vs. docetaxel for metastatic hormone-sensitive prostate cancer: A microsimulation model |
| Q30244818 | Addressing taxane resistance in metastatic castration-resistant prostate cancer: a focus on chaperone proteins |
| Q38244522 | Advanced prostate cancer - patient survival and potential impact of enzalutamide and other emerging therapies |
| Q38282461 | Advances in systemic therapies for metastatic castration-resistant prostate cancer |
| Q36416370 | Androgen pathway resistance in prostate cancer and therapeutic implications |
| Q33775723 | Androgen receptor as a driver of therapeutic resistance in advanced prostate cancer |
| Q36414184 | Androgen receptor splice variants circumvent AR blockade by microtubule-targeting agents |
| Q30577613 | Androgen receptor splice variants determine taxane sensitivity in prostate cancer |
| Q38865487 | Androgen receptor targeted therapies in castration-resistant prostate cancer: Bench to clinic. |
| Q38977288 | Androgen receptor variation affects prostate cancer progression and drug resistance |
| Q33621403 | Androgen synthesis inhibitors in the treatment of castration-resistant prostate cancer |
| Q36823066 | Assessing the utility of cabazitaxel in mCRPC |
| Q55007455 | Baseline prostate-specific antigen levels following treatment with abiraterone acetate as a prognostic factor in castration-resistant prostate cancer. |
| Q38364635 | Battling resistance mechanisms in antihormonal prostate cancer treatment: Novel agents and combinations |
| Q38223782 | Bioclinical parameters driving decision-making of subsequent lines of treatment in metastatic castration-resistant prostate cancer |
| Q43433131 | CAST: A retrospective analysis of cabazitaxel and abiraterone acetate sequential treatment in patients with metastatic castrate-resistant prostate cancer previously treated with docetaxel. |
| Q27008883 | Chemotherapy and its evolving role in the management of advanced prostate cancer |
| Q38774654 | Chemotherapy for metastatic castrate-sensitive prostate cancer |
| Q38183819 | Clinical Evaluation of Abiraterone in the Treatment of Metastatic Prostate Cancer |
| Q42125663 | Clinical activity of enzalutamide versus docetaxel in men with castration-resistant prostate cancer progressing after abiraterone |
| Q87278875 | Clinical characteristics and prognostic factors of prostate cancer with liver metastases |
| Q35932706 | Comparative analysis of the effectiveness of abiraterone before and after docetaxel in patients with metastatic castration-resistant prostate cancer |
| Q39092924 | Contemporary agents in the management of metastatic castration-resistant prostate cancer. |
| Q26866036 | Current clinical challenges in prostate cancer |
| Q38232184 | Cytotoxic chemotherapy in the contemporary management of metastatic castration-resistant prostate cancer (mCRPC). |
| Q42728599 | Determining the optimal treatment for metastatic castration-resistant prostate cancer: age should not be a factor |
| Q63966580 | Docetaxel followed by abiraterone in metastatic castration-resistant prostate cancer: efficacy and predictive parameters in a large single center cohort |
| Q39205202 | Docetaxel rechallenge after an initial good response in patients with metastatic castration-resistant prostate cancer. |
| Q26796704 | Drug resistance in castration resistant prostate cancer: resistance mechanisms and emerging treatment strategies |
| Q38566800 | Drug therapies for metastatic castration-resistant prostate cancer |
| Q38586459 | Emerging agents for the therapy of advanced prostate cancer |
| Q58087750 | Enzalutamide therapy for advanced prostate cancer: efficacy, resistance and beyond |
| Q38212716 | Evolution of androgen receptor targeted therapy for advanced prostate cancer |
| Q36243639 | First-line non-cytotoxic therapy in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: a systematic review of 10 randomised clinical trials. |
| Q42139907 | Further analysis of PREVAIL: enzalutamide use in chemotherapy-naïve men with metastatic castration-resistant prostate cancer |
| Q55004240 | HepaCAM inhibits the malignant behavior of castration-resistant prostate cancer cells by downregulating Notch signaling and PF-3084014 (a γ-secretase inhibitor) partly reverses the resistance of refractory prostate cancer to docetaxel and enzalutami |
| Q91045350 | Impact of new systemic therapies on overall survival of patients with metastatic castration-resistant prostate cancer in a hospital-based registry |
| Q48257766 | Impact of prior androgen receptor-axis-targeted agents on the clinical activity of subsequent docetaxel in patients with metastatic castration-resistant prostate cancer: comparative assessment between abiraterone acetate and enzalutamide. |
| Q89098982 | Impact of taxanes on androgen receptor signaling |
| Q38195921 | Implementing newer agents for the management of castrate-resistant prostate cancer: what is known and what is needed? |
| Q40755361 | Importance of cycles of chemotherapy and postdocetaxel novel therapies in metastatic castration-resistant prostate cancer |
| Q36910062 | Increased chemosensitivity via targeting testicular nuclear receptor 4 (TR4)-Oct4-interleukin 1 receptor antagonist (IL1Ra) axis in prostate cancer CD133+ stem/progenitor cells to battle prostate cancer |
| Q89068388 | Intra versus Inter Cross-resistance Determines Treatment Sequence between Taxane and AR-Targeting Therapies in Advanced Prostate Cancer |
| Q38744269 | Intracellular kinetics of the androgen receptor shown by multimodal Image Correlation Spectroscopy (mICS). |
| Q46349563 | Is there an optimal treatment sequencing strategy for metastatic castration-resistant prostate cancer? |
| Q42096514 | Is there still a place for docetaxel rechallenge in prostate cancer? |
| Q35879087 | Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. |
| Q38098596 | Metabolic and toxicological considerations of newly approved prostate cancer drugs |
| Q38181005 | Metastatic castration-resistant prostate cancer (CRPC): preclinical and clinical evidence for the sequential use of novel therapeutics |
| Q38312041 | Metastatic castration-resistant prostate cancer: time for innovation |
| Q39173425 | Navigating the evolving therapeutic landscape in advanced prostate cancer |
| Q55981202 | New agents for prostate cancer |
| Q38206684 | New developments in the treatment of castration resistant prostate cancer |
| Q38241095 | No clear evidence of a clinical benefit of a sequential therapy regimen with abiraterone acetate and enzalutamide |
| Q48110667 | No significant impact of prior treatment profile with docetaxel on the efficacy of cabazitaxel in Japanese patients with metastatic castration-resistant prostate cancer. |
| Q49593012 | No significant impact of response to prior androgen receptor-axis-targeted agents on the efficacy of subsequent docetaxel in patients with metastatic castration-resistant prostate cancer |
| Q38574684 | Novel agents for castration-resistant prostate cancer: Early experience and beyond |
| Q54949068 | Novel anti-androgen receptor signaling agents: Understanding the mechanisms of resistance. |
| Q26796568 | ODM-201: a new-generation androgen receptor inhibitor in castration-resistant prostate cancer |
| Q40608123 | Optimal sequencing of docetaxel and abiraterone in men with metastatic castration-resistant prostate cancer |
| Q38097373 | Optimal therapy sequencing in metastatic castration-resistant prostate cancer |
| Q55020070 | Optimizing the treatment of metastatic castration-resistant prostate cancer: a Latin America perspective. |
| Q92885737 | Pantoprazole Affecting Docetaxel Resistance Pathways via Autophagy (PANDORA): Phase II Trial of High Dose Pantoprazole (Autophagy Inhibitor) with Docetaxel in Metastatic Castration-Resistant Prostate Cancer (mCRPC) |
| Q36981441 | Partial response of liver metastases treated with abiraterone in castration-resistant prostate cancer: A case report |
| Q35328550 | Phase 1/2 study of orteronel (TAK-700), an investigational 17,20-lyase inhibitor, with docetaxel-prednisone in metastatic castration-resistant prostate cancer |
| Q37735587 | Phase I/II trial of cabazitaxel plus abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and abiraterone |
| Q34070638 | Practical guide to the use of abiraterone in castration resistant prostate cancer |
| Q55439000 | Precision medicine applications in prostate cancer. |
| Q57115965 | Predicting Response and Recognizing Resistance: Improving Outcomes in Patients With Castration-resistant Prostate Cancer |
| Q55441916 | Predictors of duration of abiraterone acetate in men with castration-resistant prostate cancer. |
| Q39140827 | Prognostic and predictive value of plasma testosterone levels in patients receiving first-line chemotherapy for metastatic castrate-resistant prostate cancer |
| Q38826609 | Progress in the mechanism and drug development of castration-resistant prostate cancer |
| Q35602593 | Prospective evaluation of low-dose ketoconazole plus hydrocortisone in docetaxel pre-treated castration-resistant prostate cancer patients |
| Q57121731 | Prostate cancer |
| Q87402141 | Prostate cancer: treatment sequencing for CRPC--what do we know? |
| Q92967284 | Prostate-specific membrane antigen in circulating tumor cells is a new poor prognostic marker for castration-resistant prostate cancer |
| Q27011642 | Quo vadis: advanced prostate cancer-clinical care and clinical research in the era of multiple androgen receptor-directed therapies |
| Q36410270 | Randomized, Noncomparative, Phase II Trial of Early Switch From Docetaxel to Cabazitaxel or Vice Versa, With Integrated Biomarker Analysis, in Men With Chemotherapy-Naïve, Metastatic, Castration-Resistant Prostate Cancer |
| Q85350364 | Real-world experience with abiraterone |
| Q53737270 | Rechallenge of docetaxel combined with epirubicin given on a weekly schedule in advanced castration-resistant prostate cancer patients previously exposed to docetaxel and abiraterone acetate: a single-institution experience. |
| Q38530028 | Role of chemotherapy in the treatment of metastatic castration-resistant prostate cancer patients who have progressed after abiraterone acetate. |
| Q38726366 | Role of taxanes in advanced prostate cancer. |
| Q34553405 | SEOM clinical guidelines for the treatment of metastatic prostate cancer |
| Q38525119 | Sequencing of agents in castration-resistant prostate cancer |
| Q27022715 | Sequential use of novel therapeutics in advanced prostate cancer following docetaxel chemotherapy |
| Q24289204 | Should docetaxel be standard of care for patients with metastatic hormone-sensitive prostate cancer? Pro and contra |
| Q39016544 | Strategies to avoid treatment-induced lineage crisis in advanced prostate cancer |
| Q39612278 | Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302. |
| Q48333900 | Systemic immune-inflammation index predicts the combined clinical outcome after sequential therapy with abiraterone and docetaxel for metastatic castration-resistant prostate cancer patients. |
| Q26795445 | Targeting molecular resistance in castration-resistant prostate cancer |
| Q38797560 | Targeting persistent androgen receptor signaling in castration-resistant prostate cancer |
| Q27022821 | Targeting the adaptive molecular landscape of castration-resistant prostate cancer |
| Q48986833 | Targeting the androgen receptor in metastatic castration-resistant prostate cancer |
| Q26995692 | Targeting the androgen receptor with steroid conjugates |
| Q49587940 | Testosterone Diminishes Cabazitaxel Efficacy and Intratumoral Accumulation in a Prostate Cancer Xenograft Model. |
| Q38508128 | The development of abiraterone acetate for castration-resistant prostate cancer |
| Q37227713 | The effect of prior androgen synthesis inhibition on outcomes of subsequent therapy with docetaxel in patients with metastatic castrate-resistant prostate cancer: results from a retrospective analysis of a randomized phase 3 clinical trial (CALGB 90 |
| Q45943517 | The evolution of chemotherapy for the treatment of prostate cancer. |
| Q38266909 | The evolution of prostate cancer therapy: targeting the androgen receptor |
| Q33946666 | The influence of prior abiraterone treatment on the clinical activity of docetaxel in men with metastatic castration-resistant prostate cancer |
| Q57105371 | The role of ketoconazole in current prostate cancer care |
| Q38090812 | Treatment options in castration-resistant prostate cancer: current therapies and emerging docetaxel-based regimens |
| Q38199939 | Treatment sequencing in metastatic castrate-resistant prostate cancer |
| Q53792451 | Understanding taxanes in prostate cancer; importance of intratumoral drug accumulation. |
| Q36909750 | Very Early PSA Response to Abiraterone in mCRPC Patients: A Novel Prognostic Factor Predicting Overall Survival |
| Q38587547 | What do we know about treatment sequencing of abiraterone, enzalutamide, and chemotherapy in metastatic castration-resistant prostate cancer? |
| Q87286468 | [Metastasized prostate cancer. Position paper on the use of chemotherapy] |
| Q52837349 | [Metastatic prostate cancer : Update: position paper for the use of chemotherapy]. |
Search more.